Results 271 to 280 of about 252,763 (309)

VX-950 (Vertex/Mitsubishi).

Current opinion in investigational drugs (London, England : 2000), 2005
Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection.
openaire   +2 more sources

VX Percutaneous Studies in Man

1960
Abstract : The effect of percutaneous administration of VX on 103 subjects using 50, 100, 200 mu aerosol particles, single and multiple drops, was studied. VX as neat agent, in doses from 5 to 35 microgram/kg, was applied to the skin of right volar forearm, or hand, or neck.
Jane L. Stubbs, V. M. Sim
openaire   +1 more source

PRELIMINARY GROUP CLASSIFICATION OF EQUATION vt = f ( x,vx ) vxx + g ( x,vx )

Acta Mathematica Scientia, 1997
Abstract Using the method of preliminary group classification introduced by Ibragimov et al[J. Math. Phys. 32, 2988(1991)], we give a classification of equations vt = f(x, vx)vxx + g(x,vx) which admitting an extension by one of the principal Lie algebra of the equation.
openaire   +1 more source

VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis.

Experimental Cell Research, 2020
Yiyi Li, X. Niu, Haitao Xu, Qingwen Li, Lanxia Meng, Mingyang He, Jie Zhang, Zhentao Zhang, Zhaohui Zhang   +8 more
semanticscholar   +1 more source

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.

Pharmacology and Therapeutics, 2020
L. Górecki, M. Andrs, M. Řezáčová, J. Korábečný   +3 more
semanticscholar   +1 more source

VX-497

Drugs of the Future, 2000
null Sorbera, L.A., null Silvestre, J.S., null Castaner, J., null Martin, L.   +3 more
openaire   +1 more source

Russian VX

2020
Vladimir Rembovskiy, Elena Savelieva, Andrey Radilov, Natalia Samchenko, Georgy Karakashev, Mikhail Leninskiy, Nadezhda Koryagina, Sergey Kuznetsov, Igor Mindukshev, Natalia Khlebnikova, Richard Jenkins, Nikolay Goncharov   +11 more
openaire   +1 more source

VX-745. Vertex Pharmaceuticals.

Current opinion in investigational drugs (London, England : 2000), 2002
VX-745, a lead anti-inflammatory candidate, small-molecule inhibitor of mitogen-activated protein kinase (MAPK), is under development by Vertex Pharmaceuticals Inc in association with Kissei Pharmaceutical Co Ltd for the potential treatment of rheumatoid arthritis (RA) [214928].
openaire   +1 more source

VX

2014
R.A. Moyer, F.R. Sidell, H. Salem
openaire   +1 more source

VX

2005
Harry Salem, Frederick R. Sidell
openaire   +1 more source